Flexible laboratory and good manufacturing practice-ready infrastructure in Basel is designed to support biopharma startups, manufacturing scale-up, and innovation growth, says SENN Development CEO Dr. Johannes Eisenhut.
Johannes Eisenhut
Advertisement
Johannes Eisenhut, PhD, is CEO of SENN Development.
Articles by Johannes Eisenhut
SENN Development CEO Dr. Johannes Eisenhut discusses how Basel’s expanding life sciences ecosystem supports biopharma innovation through research infrastructure and specialized talent growth.
Advertisement
Latest Updated Articles
Advertisement
Advertisement